Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "financial-performance"

66 News Found

Morepen to add 1,000 medical representatives
News | April 12, 2025

Morepen to add 1,000 medical representatives

The company is targeting a Rs. 1,000 crore finished dosages business within the next five years


Zydus to acquire majority stake in Amplitude Surgical, France
News | March 12, 2025

Zydus to acquire majority stake in Amplitude Surgical, France

Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies


Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
News | February 14, 2025

Lupin Q3 FY25 profit up 40% at Rs. 855 Cr

Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore


Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr
News | February 03, 2025

Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr

Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,


Biocon posts Q3 FY25 PAT at Rs. 25 Cr
News | January 31, 2025

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars


Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
News | January 24, 2025

Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25

PAT after MI is Rs. 41 crore which is 162% increase


AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
News | November 14, 2024

AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr

We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%


JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
News | November 07, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth


Amcor appoints Peter Konieczny as CEO
People | September 06, 2024

Amcor appoints Peter Konieczny as CEO

Konieczny has served as Interim CEO since April 2024


Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split
News | August 30, 2024

Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split

The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector